IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
GB9516709D0
(en)
*
|
1995-08-15 |
1995-10-18 |
Zeneca Ltd |
Medicament
|
US6313127B1
(en)
|
1996-02-02 |
2001-11-06 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
GB9602166D0
(en)
|
1996-02-02 |
1996-04-03 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
CN1228087A
(zh)
*
|
1996-08-14 |
1999-09-08 |
曾尼卡有限公司 |
取代的嘧啶衍生物和它们的药物用途
|
UA56197C2
(uk)
*
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Гетероциклічні похідні
|
EP0966460A1
(en)
|
1997-02-13 |
1999-12-29 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
GB9801231D0
(en)
*
|
1997-06-05 |
1998-03-18 |
Merck & Co Inc |
A method of treating cancer
|
KR100375421B1
(ko)
*
|
1997-07-15 |
2003-05-12 |
주식회사 엘지생명과학 |
항암효과를갖는파네실전이효소저해제
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
US6387903B1
(en)
|
1997-08-27 |
2002-05-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6160118A
(en)
*
|
1998-07-01 |
2000-12-12 |
Merck & Co., Inc. |
Process for the synthesis of substituted piperazinones via Mitsunobu reaction
|
WO2000001674A1
(en)
*
|
1998-07-01 |
2000-01-13 |
Merck & Co., Inc. |
Process for making 1,5-disubstituted imidazoles
|
AU4844599A
(en)
*
|
1998-07-01 |
2000-01-24 |
Merck & Co., Inc. |
Process for the synthesis of substituted piperazinones via mitsunobu reaction
|
US6562823B1
(en)
|
1998-07-02 |
2003-05-13 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
HRP990246A2
(en)
|
1998-08-07 |
2000-06-30 |
Du Pont Pharm Co |
Succinoylamino benzodiazepines as inhibitors of a beta protein production
|
NZ509241A
(en)
|
1998-08-07 |
2003-08-29 |
Du Pont Pharm Co |
Succinoylamino lactams as inhibitors of alpha-beta protein production
|
BR9917082A
(pt)
*
|
1998-12-24 |
2001-11-06 |
Du Pont Pharm Co |
Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
WO2000051614A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferases
|
EP1158982A4
(en)
|
1999-03-03 |
2002-06-12 |
Merck & Co Inc |
Prenyl protein transferase inhibitors
|
US6355643B1
(en)
|
1999-03-03 |
2002-03-12 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU4005300A
(en)
*
|
1999-03-03 |
2000-09-21 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU3247700A
(en)
|
1999-03-03 |
2000-09-21 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
WO2000059930A1
(en)
*
|
1999-04-05 |
2000-10-12 |
Merck & Co., Inc. |
A method of treating cancer
|
WO2000075135A1
(en)
*
|
1999-06-09 |
2000-12-14 |
Merck & Co., Inc. |
Biaryl inhibitors of prenyl-protein transferase
|
US6458935B1
(en)
*
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
WO2001007437A1
(en)
*
|
1999-07-21 |
2001-02-01 |
Merck & Co., Inc. |
Crystal forms of 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone
|
US6333335B1
(en)
|
1999-07-23 |
2001-12-25 |
Merck & Co., Inc. |
Phenyl-protein transferase inhibitors
|
CA2384151A1
(en)
|
1999-09-09 |
2001-03-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6503902B2
(en)
|
1999-09-13 |
2003-01-07 |
Bristol-Myers Squibb Pharma Company |
Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
|
US6960576B2
(en)
|
1999-09-13 |
2005-11-01 |
Bristol-Myers Squibb Pharma Company |
Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
|
WO2001027108A1
(en)
|
1999-10-08 |
2001-04-19 |
Bristol-Myers Squibb Pharma Company |
AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
|
AU2001227755A1
(en)
|
2000-01-12 |
2001-07-24 |
Merck And Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6525044B2
(en)
|
2000-02-17 |
2003-02-25 |
Bristol-Myers Squibb Company |
Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
|
US6495540B2
(en)
|
2000-03-28 |
2002-12-17 |
Bristol - Myers Squibb Pharma Company |
Lactams as inhibitors of A-β protein production
|
CN1434803A
(zh)
|
2000-04-03 |
2003-08-06 |
布里斯托尔-迈尔斯斯奎布药品公司 |
作为Aβ蛋白质产生抑制剂的环内酰胺
|
MXPA02009755A
(es)
*
|
2000-04-03 |
2003-03-27 |
Bristol Myers Squibb Pharma Co |
Lactamas ciclicas como inhibidores de la produccion de proteina a-beta.
|
AU2001253246A1
(en)
|
2000-04-10 |
2001-10-23 |
Merck And Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU2001251444A1
(en)
|
2000-04-10 |
2001-10-23 |
Merck And Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US20040110764A1
(en)
*
|
2000-04-10 |
2004-06-10 |
Stump Craig A. |
Inhibitors of prenyl-protein transferase
|
US20100009966A1
(en)
*
|
2001-04-11 |
2010-01-14 |
Bristol-Myers Squibb Pharma Company |
Substituted lactams as inhibitors of abeta protein production
|
US6632812B2
(en)
*
|
2000-04-11 |
2003-10-14 |
Dupont Pharmaceuticals Company |
Substituted lactams as inhibitors of Aβ protein production
|
AU2001261728A1
(en)
*
|
2000-05-17 |
2001-11-26 |
Bristol-Myers Squibb Pharma Company |
Use of small molecule radioligands for diagnostic imaging
|
GB0012718D0
(en)
*
|
2000-05-24 |
2000-07-19 |
Angeletti P Ist Richerche Bio |
Conjugates of aminodrugs
|
CA2379445C
(en)
*
|
2000-06-01 |
2007-08-21 |
Bristol-Myers Squibb Pharma Company |
Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production
|
US20090062256A1
(en)
*
|
2001-06-01 |
2009-03-05 |
Bristol-Myers Squibb Pharma Company |
LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
|
US7354923B2
(en)
*
|
2001-08-10 |
2008-04-08 |
Palatin Technologies, Inc. |
Piperazine melanocortin-specific compounds
|
US7456184B2
(en)
*
|
2003-05-01 |
2008-11-25 |
Palatin Technologies Inc. |
Melanocortin receptor-specific compounds
|
US7732451B2
(en)
*
|
2001-08-10 |
2010-06-08 |
Palatin Technologies, Inc. |
Naphthalene-containing melanocortin receptor-specific small molecule
|
EP1425029A4
(en)
*
|
2001-08-10 |
2006-06-07 |
Palatin Technologies Inc |
PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
|
US7718802B2
(en)
|
2001-08-10 |
2010-05-18 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
US7655658B2
(en)
*
|
2001-08-10 |
2010-02-02 |
Palatin Technologies, Inc. |
Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
|
US7727991B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific single acyl piperazine compounds
|
US7968548B2
(en)
|
2003-05-01 |
2011-06-28 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine compounds with diamine groups
|
US7727990B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine and keto-piperazine compounds
|
CA2533369C
(en)
|
2003-07-22 |
2009-07-14 |
Arena Pharmaceuticals, Inc. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
US7176635B2
(en)
*
|
2004-02-24 |
2007-02-13 |
Musco Corporation |
Apparatus and method for compensating for reduced light output of a light source having a lumen depreciation characteristic over its operational life
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089518A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Uch-l1 expression and cancer therapy
|
US20060106060A1
(en)
*
|
2004-03-18 |
2006-05-18 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
WO2005089502A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
US20050288298A1
(en)
*
|
2004-03-18 |
2005-12-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US7709484B1
(en)
|
2004-04-19 |
2010-05-04 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
KR101155335B1
(ko)
*
|
2005-01-07 |
2012-06-11 |
엘지전자 주식회사 |
이동통신 단말기의 멀티미디어 메시지 동작방법
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
EP3466953B1
(en)
|
2005-12-13 |
2021-02-03 |
Incyte Holdings Corporation |
Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor
|
US7834017B2
(en)
|
2006-08-11 |
2010-11-16 |
Palatin Technologies, Inc. |
Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
|
SI2173752T2
(sl)
|
2007-06-13 |
2022-09-30 |
Incyte Holdings Corporation |
Soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4- il)-1h-pirazol-1-il)-3-ciklopentilpropannitrila
|
ES2421237T7
(es)
|
2007-08-15 |
2013-09-30 |
Arena Pharmaceuticals, Inc. |
Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
|
US7767826B2
(en)
*
|
2007-10-05 |
2010-08-03 |
Pharmatech International, Inc. |
Process for the synthesis of L-(+)-ergothioneine
|
EP2543368A1
(en)
|
2007-12-11 |
2013-01-09 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
CN104784173B
(zh)
|
2008-10-28 |
2019-07-26 |
艾尼纳制药公司 |
用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
BRPI0920927A2
(pt)
*
|
2008-11-13 |
2019-09-24 |
Link Medicine Corp |
derivados de azaquinolinona e usos dos mesmos
|
US8247990B1
(en)
|
2008-12-05 |
2012-08-21 |
Musco Corporation |
Apparatus, method, and system for improved switching methods for power adjustments in light sources
|
MX2011012353A
(es)
*
|
2009-05-22 |
2011-12-14 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
|
AR076920A1
(es)
|
2009-05-22 |
2011-07-20 |
Incyte Corp |
3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
|
AR078012A1
(es)
*
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
AR081315A1
(es)
*
|
2010-03-10 |
2012-08-08 |
Incyte Corp |
Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
|
CN103002875B
(zh)
|
2010-05-21 |
2016-05-04 |
因塞特控股公司 |
Jak抑制剂的局部用制剂
|
CA2801074A1
(en)
|
2010-06-04 |
2011-12-08 |
Albany Molecular Research, Inc. |
Glycine transporter-1 inhibitors, methods of making them, and uses thereof
|
JP6034784B2
(ja)
|
2010-07-28 |
2016-11-30 |
ジャンセン ダイアグノスティックス,エルエルシー |
ファルネシルトランスフェラーゼ阻害剤による治療に対する急性白血病応答を判定するための方法
|
BR112013012502A2
(pt)
|
2010-11-19 |
2019-03-06 |
Incyte Corporation |
pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
|
EP2640725B1
(en)
|
2010-11-19 |
2015-01-07 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
MX344479B
(es)
|
2011-06-20 |
2016-12-16 |
Incyte Holdings Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak).
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
WO2013173720A1
(en)
|
2012-05-18 |
2013-11-21 |
Incyte Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
UA120834C2
(uk)
|
2012-11-15 |
2020-02-25 |
Інсайт Холдінгс Корпорейшн |
Лікарські форми руксолітинібу зі сповільненим вивільненням
|
RS58547B1
(sr)
|
2013-03-06 |
2019-05-31 |
Incyte Holdings Corp |
Postupci i intermedijeri za dobijanje inhibitora jak
|
DK2968316T3
(da)
|
2013-03-13 |
2019-10-07 |
Forma Therapeutics Inc |
2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-on-derivater og relaterede forbindelser som fedtsyresyntase (fasn)-inhibitorer til behandlingen af cancer
|
MY195091A
(en)
|
2013-08-07 |
2023-01-10 |
Incyte Corp |
Sustained Release Dosage Forms for a JAK1 Inhibitor
|
WO2015070367A1
(en)
*
|
2013-11-12 |
2015-05-21 |
Merck Sharp & Dohme Corp. |
Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
LT3209655T
(lt)
|
2014-10-24 |
2021-01-11 |
Landos Biopharma, Inc. |
Medicininiai preparatai į lantionino sintezę c panašaus baltymo 2 pagrindu
|
MX2017016413A
(es)
|
2015-06-12 |
2018-08-01 |
Axovant Sciences Gmbh |
Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
|
TW201720439A
(zh)
|
2015-07-15 |
2017-06-16 |
Axovant Sciences Gmbh |
用於預防及治療與神經退化性疾病相關的幻覺之作為5-ht2a血清素受體的二芳基及芳基雜芳基脲衍生物
|
KR101885361B1
(ko)
|
2015-08-17 |
2018-08-06 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법
|
JP2019534290A
(ja)
|
2016-11-03 |
2019-11-28 |
クラ オンコロジー, インコーポレイテッド |
癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
|
IL283725B2
(en)
|
2017-06-20 |
2024-04-01 |
Imbria Pharmaceuticals Inc |
Preparations and methods for increasing the efficiency of heart metabolism
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
SG11202007164UA
(en)
|
2018-01-30 |
2020-08-28 |
Incyte Corp |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
KR20210018203A
(ko)
|
2018-03-30 |
2021-02-17 |
인사이트 코포레이션 |
Jak 억제제를 사용하는 화농성 한선염의 치료
|
EP3873214A4
(en)
|
2018-10-29 |
2022-07-13 |
Forma Therapeutics, Inc. |
SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[D]IMIDAZOL-5-YL)BENZOYL)PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
CN113748109B
(zh)
|
2019-12-20 |
2023-07-21 |
朗多生物制药股份有限公司 |
羊毛硫氨酸c样蛋白2配体、用所述配体制备的细胞以及使用所述配体的疗法
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|